ADA conference spotlights triple hormone receptors, a monthly obesity drug and mixed outcomes

The American Diabetes Association’s annual meeting in New Orleans featured updates on emerging diabetes therapies. Speakers highlighted research on drugs that target three hormone receptors simultaneously, a strategy aimed at improving glucose control and weight management.

A new monthly injectable obesity medication was also discussed, offering a potential alternative to daily treatments. Attendees noted its promise but emphasized the need for further data.

The session concluded with a bittersweet tone, acknowledging progress while recognizing ongoing challenges in achieving lasting disease control.